Visceral Pain Treatment Market value is projected to reach US$ 19.55 Bn at the end of the forecast period and it is expected to grow at the CAGR of 5.3%. The global Visceral Pain Treatment market report is a comprehensive analysis of the industry, market, and key players. The report has covered the market by demand and supply-side by segments. The global Visceral Pain Treatment report also provides trends by market segments, technology, and investment with a competitive landscape.Visceral Pain Treatment Market Overview:
Visceral pain can be caused by injuries to organs such as the gallbladder, intestines, bladder, or kidneys. This causes visceral pain that ranges from severe, persistent, to very deep discomfort that feels like it's squeezing out of the body. Medications including painkillers, spasmolytics, and antidepressants are used for symptomatic therapy.To know about the Research Methodology :- Request Free Sample Report
Global Visceral Pain Treatment Market Dynamics:
Drivers:
Over the forecast period, increased awareness of visceral pain and the increasing prevalence of the condition is expected to fuel market growth. To create novel therapeutics in the visceral pain treatment market, key companies in the market are heavily spending on research and development and conducting clinical studies. During the projected period, medication approvals are expected to considerably fuel market expansion and generate attractive potential possibilities in the visceral pain treatment market. In addition, the increased prevalence of irritable bowel syndrome (IBS) over the world is expected to fuel market expansion. In the United States, around 70,000 new cases of IBD are identified each year. During the years 2003–2013, the hospitalization rate of secondary diagnosed IBD patients grew dramatically, rising from 44.2 to 59.7 per 100,000 people. Irritable bowel syndrome (IBS), which is becoming more common, is likely to boost market development. Irritable bowel syndrome affects between 10% and 15% of individuals worldwide each year, according to the IFFBD (International Foundation for Gastrointestinal Disorders). Shortly, the recent introduction and approval of new medications in North America, Europe, and Japan are expected to increase demand for visceral pain therapy. MEDI2070 interleukin-23 monoclonal antibody is being developed by AstraZeneca and Allergan to treat ulcerative colitis and Crohn's disease. The MEDI2070 is now being tested in phase IIb clinical trial for moderate to severe Crohn's disease and clinical trial phase II for ulcerative colitis PF-00547659 by Pfizer and Ozanimod by Celgene are in phase II and phase III clinical trials, respectively, for Crohn's disease and ulcerative colitis.Restraints:
However, a key issue that is predicted to stymie the growth of the visceral pain treatment market is the absence of particular therapy for visceral pain conditions such as irritable bowel syndrome and Crohn's disease. Furthermore, rivalry among leading industry players for the discovery of innovative medications for visceral pain is predicted to be a major factor limiting the market's expansion. Furthermore, throughout the projected period, the high cost of medications, and patent expiration of leading pharmaceuticals are likely to be a key impediment to the growth of the visceral pain treatment market.Global Visceral Pain Treatment Market Segment Analysis:
Based on Drug Type, the analgesics category dominated the market, in 2022. Non-opioid analgesics are the first-line therapy for visceral pain. Aleve (naproxen) and aspirin are two over-the-counter non-steroidal anti-inflammatories (NSAIDs) analgesics that are commonly used to relieve visceral discomfort (acetylsalicylic acid). Under the firms' previously announced interim exclusive supply and distribution agreement, the FDA approved Levothyroxine Sodium Tablets USP, an opioid pain medication. Baudax Bio was founded as a new pharmaceutical firm to develop non-opioid analgesic medicines that are both effective and safe. Based on Indication, the ulcerative colitis segment held the highest market share, followed by the Crohn's disease segment. Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), is a chronic inflammatory condition with an unknown cause.In the recent several decades, there has been a significant increase in the frequency and incidence of IBDs, which is expected to continue over the projection period. According to IBD Support Australia Incorporated, inflammatory bowel disease affects roughly 61,000 people in Australia, with Crohn's disease affecting 28,000 individuals and ulcerative colitis affecting 33,000. Based on Distribution Channel, the retail pharmacies segment held a large part of the market in 2022, and this trend is likely to continue during the projected period, in terms of revenue. Due to favorable demographic circumstances and an epidemiological change, the retail pharmacy industry has seen tremendous development in recent years. The segment is expected to grow due to the inclusion of many drugs within the OTC category and a preference for self-medication.
Regional Insights:
North America dominated the visceral pain treatment market in 2022 and is expected to continue dominating the industry over the forecast period. This dominance is largely due to pharmaceutical firms' increased attention on R&D and cooperative partnerships to create new medications for visceral pain. In addition, the increased prevalence of irritable bowel syndrome and Crohn's disease is expected to drive regional market expansion throughout the projection period. Irritable bowel disease (IBD), such as ulcerative colitis or Crohn's disease, was diagnosed in roughly 3 million persons in 2015, according to the Centers for Disease Control and Prevention (CDC). Furthermore, due to increased expenditures by pharma firms and government programs for visceral pain treatment, the Asia Pacific region is expected to develop at the quickest rate throughout the projection period. In the Asia Pacific area, firms including Glenmark Pharmaceuticals, Takeda Pharmaceutical Company, and others sell visceral pain medications and treatments. Additionally, government agencies such as the Australian government are working to raise knowledge of visceral discomfort and how to treat it. The objective of the report is to present a comprehensive analysis of the global Visceral Pain Treatment market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the global Visceral Pain Treatment market dynamics, structure by analyzing the market segments and project the global Visceral Pain Treatment market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global Visceral Pain Treatment market make the report investor’s guide.Global Visceral Pain Treatment Market Key Developments:
In August 2021, under the terms of a recently announced interim exclusive supply and distribution agreement, Lannett Company, Inc. has launched Cediprof, Inc.'s FDA-approved Levothyroxine Sodium Tablets USP, an opioid pain reliever. In February 2021, The Drugs for Neglected Diseases Initiative (DNDi) and Novartis have agreed to work together to develop ‘LXE408' as a potential new therapy for visceral leishmaniasis, which is one of the world's major parasite killers. LXE408, a first-in-class chemical, was discovered with financial assistance from Novartis' Welcome Trust. In January 2021, Ironwood Pharmaceuticals Inc., a biotechnology company based in the United States, announced that the National Medical Products Administration has approved the marketing applications of LINZESS® (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) in China and that the launch will take place in the second half of 2021 with its Chinese partner, AstraZeneca.Global Visceral Pain Treatment Market Scope: Inquire before buying
Global Visceral Pain Treatment Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 13.61 Bn. Forecast Period 2023 to 2029 CAGR: 5.3% Market Size in 2029: US $ 19.55 Bn. Segments Covered: by Drug Type Analgesics Narcotics NSAID Pain Modifiers Tricyclic Antidepressants Tricyclic Anticonvulsant Others by Indication Interstitial Cystitis Crohn’s Irritable Bowel Chronic Prostatitis by Distribution Channel Hospital Pharmacy Online Pharmacy Retail Pharmacy by Application In-patient Out-patient Visceral Pain Treatment Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Global Visceral Pain Treatment Market Key Players
1. Addex Therapeutics Ltd 2. AstraZeneca 3. Astellas Pharma Inc. 4. Neurim Pharmaceuticals Ltd. 5. Abbvie 6. Pfizer Inc 7. Glcare Pharma Inc 8. Chromocell Corporation 9. Allergan Inc 10.Johnson & Johnson Services Inc 11.Grunenthal GmbH 12.Takeda Pharmaceutical Company Limited 13.Medestea Research & Production S.p.A 14.Novartis AG 15.Sanofi 16.GlaxoSmithKline plc 17.Glenmark Pharmaceuticals 18.Other Key Players Frequently Asked Questions: 1. Which region has the largest share in Global Visceral Pain Treatment Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Visceral Pain Treatment Market? Ans: The Global Visceral Pain Treatment Market is growing at a CAGR of 5.3% during forecasting period 2023-2029. 3. What is scope of the Global Visceral Pain Treatment Market report? Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Visceral Pain Treatment Market? Ans: The important key players in the Global market are – Addex Therapeutics Ltd, AstraZeneca, Astellas Pharma Inc., Neurim Pharmaceuticals Ltd., Abbvie, Pfizer Inc, Glcare Pharma Inc, Chromocell Corporation, Allergan Inc, Johnson & Johnson Services Inc, Grunenthal GmbH, Takeda Pharmaceutical Company Limited, Medestea Research & Production S.p.A, Novartis AG, Sanofi, GlaxoSmithKline plc, Glenmark Pharmaceuticals, and Other Key Players 5. What is the study period of this Market? Ans: The Global Visceral Pain Treatment Market is studied from 2022 to 2029.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Visceral Pain Treatment Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2022 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Visceral Pain Treatment Market 3.4. Geographical Snapshot of the Visceral Pain Treatment Market, By Manufacturer share 4. Global Visceral Pain Treatment Market Overview, 2022-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Drug Types 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Visceral Pain Treatment Market 5. Supply Side and Demand Side Indicators 6. Global Visceral Pain Treatment Market Analysis and Forecast, 2022-2029 6.1. Global Visceral Pain Treatment Market Size & Y-o-Y Growth Analysis. 7. Global Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 7.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 7.1.1. Analgesics 7.1.1.1. Narcotics 7.1.1.2. NSAID 7.1.2. Pain Modifiers 7.1.2.1. Tricyclic Antidepressants 7.1.2.2. Tricyclic Anticonvulsant 7.1.2.3. Others 7.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 7.2.1. Interstitial Cystitis 7.2.2. Crohn’s 7.2.3. Irritable Bowel 7.2.4. Chronic Prostatitis 7.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 7.3.1. Hospital Pharmacy 7.3.2. Online Pharmacy 7.3.3. Retail Pharmacy 7.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 7.4.1. In-patient 7.4.2. Out-patient 8. Global Visceral Pain Treatment Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 9.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 9.1.1. Analgesics 9.1.1.1. Narcotics 9.1.1.2. NSAID 9.1.2. Pain Modifiers 9.1.2.1. Tricyclic Antidepressants 9.1.2.2. Tricyclic Anticonvulsant 9.1.2.3. Others 9.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 9.2.1. Interstitial Cystitis 9.2.2. Crohn’s 9.2.3. Irritable Bowel 9.2.4. Chronic Prostatitis 9.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 9.3.1. Hospital Pharmacy 9.3.2. Online Pharmacy 9.3.3. Retail Pharmacy 9.4. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 9.4.1. In-patient 9.4.2. Out-patient 10. North America Visceral Pain Treatment Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 11.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 11.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 11.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 11.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 12. Canada Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 12.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 12.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 12.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 12.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 13. Mexico Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 13.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 13.2. Market Size (Value) Estimates & Forecast By Indication 2022-2029 13.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 13.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 14. Europe Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 14.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 14.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 14.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 14.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 15. Europe Visceral Pain Treatment Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 16.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 16.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 16.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 16.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 17. France Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 17.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 17.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 17.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 17.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 18. Germany Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 18.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 18.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 18.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 18.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 19. Italy Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 19.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 19.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 19.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 19.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 20. Spain Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 20.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 20.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 20.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 20.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 21. Sweden Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 21.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 21.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 21.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 21.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 22. CIS Countries Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 22.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 22.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 22.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 22.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 23. Rest of Europe Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 23.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 23.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 23.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 23.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 24. Asia Pacific Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 24.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 24.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 24.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 24.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 25. Asia Pacific Visceral Pain Treatment Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 26.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 26.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 26.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 26.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 27. India Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 27.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 27.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 27.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 27.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 28. Japan Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 28.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 28.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 28.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 28.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 29. South Korea Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 29.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 29.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 29.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 29.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 30. Australia Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 30.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 30.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 30.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 30.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 31. ASEAN Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 31.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 31.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 31.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 31.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 32. Rest of Asia Pacific Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 32.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 32.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 32.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 32.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 33. Middle East Africa Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 33.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 33.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 33.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 33.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 34. Middle East Africa Visceral Pain Treatment Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 35.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 35.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 35.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 35.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 36. GCC Countries Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 36.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 36.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 36.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 36.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 37. Egypt Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 37.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 37.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 37.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 37.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 38. Nigeria Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 38.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 38.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 38.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 38.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 39. Rest of ME&A Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 39.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 39.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 39.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 39.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 40. South America Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 40.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 40.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 40.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 40.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 41. South America Visceral Pain Treatment Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 42.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 42.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 42.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 42.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 43. Argentina Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 43.1. Market Size (Value) Estimates & Forecast By Drug Type, 2022-2029 43.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 43.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 43.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 44. Rest of South America Visceral Pain Treatment Market Analysis and Forecasts, 2022-2029 44.1. Market Size (Value) Estimates & Forecast By Drug Type 2022-2029 44.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 44.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 44.4. Market Size (Value) Estimates & Forecast By Application, 2022-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Visceral Pain Treatment Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Distribution Channel, and R&D Investment 45.2.2. New Drug Type Launches and Drug Type Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. Addex Therapeutics Ltd. 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Drug Type Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. AstraZeneca 45.3.3. Astellas Pharma Inc. 45.3.4. Neurim Pharmaceuticals Ltd. 45.3.5. Abbvie 45.3.6. Pfizer Inc 45.3.7. Glcare Pharma Inc 45.3.8. Chromocell Corporation 45.3.9. Allergan Inc 45.3.10. Johnson & Johnson Services Inc 45.3.11. Grunenthal GmbH 45.3.12. Takeda Pharmaceutical Company Limited 45.3.13. Medestea Research & Production S.p.A 45.3.14. Novartis AG 45.3.15. Sanofi 45.3.16. GlaxoSmithKline plc 45.3.17. Glenmark Pharmaceuticals 45.3.18. Other Key Players 46. Primary Key Insights